ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Preventing Vision Loss: ONL Therapeutics’ David Esposito"
Episode Synopsis
Welcome to The Healthcare Technology Report, a leading information source on healthcare technology companies and solutions.
Today, we speak with David Esposito, President and CEO of ONL Therapeutics, a clinical-stage biopharmaceutical company developing treatments to protect and preserve sight for patients with retinal diseases. ONL’s lead candidate, ONL1204, is being advanced for conditions such as retinal detachment, geographic atrophy, and glaucoma, with the goal of preventing vision loss at its root cause.
David has built and scaled multiple healthcare companies through successful exits and brings deep experience leading organizations at the intersection of science and business.
David supports Harvest Time Partners Foundation. To learn more about this organization click here.
I am your host RJ Lumba. We hope you enjoy the show. If you like the episode click to follow.
Today, we speak with David Esposito, President and CEO of ONL Therapeutics, a clinical-stage biopharmaceutical company developing treatments to protect and preserve sight for patients with retinal diseases. ONL’s lead candidate, ONL1204, is being advanced for conditions such as retinal detachment, geographic atrophy, and glaucoma, with the goal of preventing vision loss at its root cause.
David has built and scaled multiple healthcare companies through successful exits and brings deep experience leading organizations at the intersection of science and business.
David supports Harvest Time Partners Foundation. To learn more about this organization click here.
I am your host RJ Lumba. We hope you enjoy the show. If you like the episode click to follow.
More episodes of the podcast The Healthcare Technology Report with RJ Lumba
MedTech Leader: PAVmed’s Lishan Aklog
29/10/2025
In God we trust